[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100557545":3},{"organization":4,"armGroups":7,"interventions":34,"overallOfficials":40,"centralContacts":45,"locations":51,"responsibleParty":229,"collaborators":40,"id":231,"slug":232,"hasResults":233,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":40,"eligibilityCriteria":237,"healthyVolunteers":238,"sex":239,"minAge":240,"maxAge":241,"enrollmentInfo":242,"targetDuration":40,"studyType":245,"phases":246,"briefSummary":248,"conditions":249,"keywords":251,"overallStatus":77,"whyStopped":40,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":267},{"fullName":5,"class":6},"BioCryst Pharmaceuticals","INDUSTRY",[8,14,19,23,27,31],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1 - BCX17725 single dose","EXPERIMENTAL","Participants randomized to BCX17725 will receive BCX17725 as a single dose in sequential ascending dose cohorts",[13],"Drug: BCX17725",{"label":15,"type":10,"description":16,"interventionNames":17},"Part 1 - placebo single dose","Participants randomized to placebo will receive placebo as a single dose",[18],"Drug: Placebo",{"label":20,"type":10,"description":21,"interventionNames":22},"Part 2 - BCX17725 multiple doses","Participants randomized to BCX17725 will receive BCX17725 as multiple doses in sequential ascending dose cohorts",[13],{"label":24,"type":10,"description":25,"interventionNames":26},"Part 2 - placebo multiple doses","Participants randomized to placebo will receive placebo as multiple doses",[18],{"label":28,"type":10,"description":29,"interventionNames":30},"Part 3 - BCX17725 multiple doses","Participants will receive BCX17725 as multiple doses",[13],{"label":32,"type":10,"description":29,"interventionNames":33},"Part 4 - BCX17725 multiple doses",[13],[35,41],{"type":36,"name":37,"description":38,"armGroupLabels":39,"otherNames":40},"DRUG","BCX17725","BCX17725 for injection",[9,20,28,32],null,{"type":36,"name":42,"description":43,"armGroupLabels":44,"otherNames":40},"Placebo","Placebo for injection",[15,24],[46],{"name":47,"role":48,"phone":49,"phoneExt":40,"email":50},"BioCryst Pharmaceuticals, Inc.","CONTACT","+1 919 859 1302","clinicaltrials@biocryst.com",[52,75,91,106,120,136,153,164,175,194,205,220],{"facility":53,"status":54,"city":55,"state":56,"zip":57,"country":58,"countryCode":59,"cosmosGeoPoint":60,"geoPoint":65,"contacts":66},"Stanford University School of Medicine","NOT_YET_RECRUITING","Palo Alto","California","94304","United States","US",{"type":61,"coordinates":62},"Point",[63,64],-122.14302,37.44188,{"lat":64,"lon":63},[67,71],{"name":68,"role":48,"phone":69,"phoneExt":40,"email":70},"Chaw-Ning Lee","650-497-7230","cnlee06@stanford.edu",{"name":72,"role":48,"phone":73,"phoneExt":40,"email":74},"Thomas Buschbacher","352-278-7603","tbusch@stanford.edu",{"facility":76,"status":77,"city":78,"state":56,"zip":79,"country":58,"countryCode":59,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"Therapeutics Clinical Research","RECRUITING","San Diego","92123",{"type":61,"coordinates":81},[82,83],-117.16472,32.71571,{"lat":83,"lon":82},[86],{"name":87,"role":48,"phone":88,"phoneExt":89,"email":90},"Hector Bailon","858-571-6800","141","hbailon@therapeuticsresearch.com",{"facility":92,"status":77,"city":93,"state":94,"zip":95,"country":58,"countryCode":59,"cosmosGeoPoint":96,"geoPoint":100,"contacts":101},"Yale Center for Clinical Investigation","New Haven","Connecticut","06519",{"type":61,"coordinates":97},[98,99],-72.92816,41.30815,{"lat":99,"lon":98},[102],{"name":103,"role":48,"phone":104,"phoneExt":40,"email":105},"Nicole Olszewski","203-785-5505","nicole.olszewski@yale.edu",{"facility":107,"status":77,"city":108,"state":109,"zip":110,"country":58,"countryCode":59,"cosmosGeoPoint":111,"geoPoint":115,"contacts":116},"Northwestern Dermatology CTU","Chicago","Illinois","60611",{"type":61,"coordinates":112},[113,114],-87.65005,41.85003,{"lat":114,"lon":113},[117],{"name":40,"role":48,"phone":118,"phoneExt":40,"email":119},"312-503-5944","NUderm-research@northwestern.edu",{"facility":121,"status":77,"city":122,"state":123,"zip":124,"country":58,"countryCode":59,"cosmosGeoPoint":125,"geoPoint":129,"contacts":130},"Dawes Fretzin Clinical Research Group, LLC","Indianapolis","Indiana","46250",{"type":61,"coordinates":126},[127,128],-86.15804,39.76838,{"lat":128,"lon":127},[131],{"name":132,"role":48,"phone":133,"phoneExt":134,"email":135},"Joannie Prusa","317-516-5030","108","jprusa@ecommunity.com",{"facility":137,"status":77,"city":138,"state":139,"zip":140,"country":141,"countryCode":142,"cosmosGeoPoint":143,"geoPoint":147,"contacts":148},"Westmead Hospital - Department of Dermatology","Sydney","New South Wales","2145","Australia","AU",{"type":61,"coordinates":144},[145,146],151.20732,-33.86785,{"lat":146,"lon":145},[149],{"name":150,"role":48,"phone":151,"phoneExt":40,"email":152},"Pablo Fernandez-Penas, MD","02 8890 5686","wslhd-dermatology-clinicaltrials@health.nsw.gov.au",{"facility":154,"status":155,"city":156,"state":157,"zip":158,"country":141,"countryCode":142,"cosmosGeoPoint":159,"geoPoint":163,"contacts":40},"Nucleus Network","COMPLETED","Brisbane","Queensland","4006",{"type":61,"coordinates":160},[161,162],153.02809,-27.46794,{"lat":162,"lon":161},{"facility":165,"status":77,"city":156,"state":157,"zip":166,"country":141,"countryCode":142,"cosmosGeoPoint":167,"geoPoint":169,"contacts":170},"Veracity Clinical Research","4102",{"type":61,"coordinates":168},[161,162],{"lat":162,"lon":161},[171],{"name":172,"role":48,"phone":173,"phoneExt":40,"email":174},"Lynda Spelman, MD","07 3039 1311","trials@veracityclinicalresearch.com.au",{"facility":176,"status":77,"city":177,"state":40,"zip":178,"country":179,"countryCode":180,"cosmosGeoPoint":181,"geoPoint":185,"contacts":186},"Hôpital Saint-Louis","Paris","75010","France","FR",{"type":61,"coordinates":182},[183,184],2.3488,48.85341,{"lat":184,"lon":183},[187,191],{"name":188,"role":48,"phone":189,"phoneExt":40,"email":190},"Emilie Fapong","01 42 49 40 62","emilie.fapong@aphp.fr",{"name":192,"role":48,"phone":189,"phoneExt":40,"email":193},"Hafsoiti Hassandjohar","hafsoiti.hassandjohar@aphp.fr",{"facility":195,"status":54,"city":196,"state":40,"zip":197,"country":198,"countryCode":199,"cosmosGeoPoint":200,"geoPoint":204,"contacts":40},"Universitätsklinikum Heidelberg","Heidelberg","69120","Germany","DE",{"type":61,"coordinates":201},[202,203],8.69079,49.40768,{"lat":203,"lon":202},{"facility":206,"status":77,"city":207,"state":40,"zip":208,"country":209,"countryCode":210,"cosmosGeoPoint":211,"geoPoint":215,"contacts":216},"Maastricht Universitair Medisch Centrum (MUMC+)","Maastricht","6229 HX","Netherlands","NL",{"type":61,"coordinates":212},[213,214],5.68889,50.84833,{"lat":214,"lon":213},[217],{"name":40,"role":48,"phone":218,"phoneExt":40,"email":219},"+31 (0)43-3875290","genodermatose@mumc.nl",{"facility":221,"status":77,"city":222,"state":40,"zip":223,"country":209,"countryCode":210,"cosmosGeoPoint":224,"geoPoint":228,"contacts":40},"Erasmus Universitair Medisch Centrum (EMC)","Rotterdam","3015 GD",{"type":61,"coordinates":225},[226,227],4.47917,51.9225,{"lat":227,"lon":226},{"type":230,"investigatorFullName":40,"investigatorTitle":40,"investigatorAffiliation":40,"oldNameTitle":40,"oldOrganization":40},"SPONSOR","100557545","phase-1-a-study-of-the-safety-tolerability-pharmacokinetics-and-immunogenicity-of-bcx17725-100557545",false,"NCT06539507","A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725","A Phase 1\u002F1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of BCX17725 in Healthy Participants and Multiple Doses of BCX17725 in Participants With Netherton Syndrome","Key Inclusion Criteria:\n\n* Male or non-pregnant, non-lactating female aged 18 to 55 years, inclusive (Parts 1 and 2), 18 to 65 years, inclusive (Part 3), or 12 to 65 years, inclusive (Part 4)\n* Confirmed diagnosis of Netherton syndrome (Parts 3 and 4)\n* IGA score of ≥ 3 (Parts 3 and 4) and IASI score of ≥ 16 (Part 4)\n* BMI between 18 and 30 kg\u002Fm\\^2, inclusive (Parts 1 and 2)\n* Estimated glomerular filtration rate (eGFR) of ≥ 90 mL\u002Fmin\u002F1.73 m\\^2 (Parts 1 and 2) or ≥ 60 mL\u002Fmin\u002F1.73 m\\^2 (Part 3)\n* Agree to follow the protocol contraception requirements from screening until 90 days after the last dose of study drug\n* In the opinion of the investigator, expected to adequately comply with all required study procedures and restrictions for the duration of the study",true,"ALL","12 Years","65 Years",{"count":243,"type":244},78,"ESTIMATED","INTERVENTIONAL",[247],"PHASE1","This is a first-in-human, Phase 1\u002F1b, 4-part study that includes the evaluation of safety, tolerability, pharmacokinetics (PK), and immunogenicity of BCX17725 when administered via single and multiple doses in healthy adult participants (Parts 1 and 2), and multiple doses in adult participants with Netherton syndrome (Part 3). In Part 4, the effectiveness, safety, and tolerability of BCX17725 when administered via multiple IV and\u002For SC doses through 12 weeks will be evaluated in adult and adolescent participants with Netherton syndrome.",[250],"Netherton Syndrome",[252,253,254,255,256,257],"First-in-human","Single ascending dose","Multiple ascending dose","Pharmacokinetics","Placebo control","Netherton syndrome","2026-06-15",{"date":260,"type":261},"2026-06-16","ACTUAL",{"date":263,"type":261},"2024-09-26",{"date":265,"type":244},"2026-12",{"name":5,"class":6},12]